Company intelligence / Profile preview
Apollomics, Inc.
United Statesapollomicsinc.com ↗
- Ownership
- Public · APLM
- Employees
- ~13
- Development stage
- Other
01
Overview
Apollomics announced top-line results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia in December 2024
- Therapeutic areas
- Oncology
- Modalities
- Targeted therapiesImmuno-oncology drugsAnti-cancer enhancers
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
Biotechnology companies in the East and West
04
Financials
- Market cap
- $49.5M
- Total revenue
- $8.5M
- Enterprise value
- $46.9M
Beyond the preview
Go deeper on Apollomics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Apollomics, Inc..